Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I, Sugiyama H. Oka Y, et al. Among authors: elisseeva oa. Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90. doi: 10.1073/pnas.0405884101. Epub 2004 Sep 13. Proc Natl Acad Sci U S A. 2004. PMID: 15365188 Free PMC article. Clinical Trial.
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H, Elisseeva OA, Masuda T, Nakano A, Kawakami M, Oji Y, Ikegame K, Hosen N, Udaka K, Yasukawa M, Ogawa H, Kawase I, Sugiyama H. Oka Y, et al. Among authors: elisseeva oa. Int J Hematol. 2003 Jul;78(1):56-61. doi: 10.1007/BF02983241. Int J Hematol. 2003. PMID: 12894852 Clinical Trial.
WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases.
Tsuboi A, Oka Y, Osaki T, Kumagai T, Tachibana I, Hayashi S, Murakami M, Nakajima H, Elisseeva OA, Fei W, Masuda T, Yasukawa M, Oji Y, Kawakami M, Hosen N, Ikegame K, Yoshihara S, Udaka K, Nakatsuka S, Aozasa K, Kawase I, Sugiyama H. Tsuboi A, et al. Among authors: elisseeva oa. Microbiol Immunol. 2004;48(3):175-84. doi: 10.1111/j.1348-0421.2004.tb03503.x. Microbiol Immunol. 2004. PMID: 15031530 Free article.
WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone.
Nakajima H, Kawasaki K, Oka Y, Tsuboi A, Kawakami M, Ikegame K, Hoshida Y, Fujiki F, Nakano A, Masuda T, Wu F, Taniguchi Y, Yoshihara S, Elisseeva OA, Oji Y, Ogawa H, Azuma I, Kawase I, Aozasa K, Sugiyama H. Nakajima H, et al. Among authors: elisseeva oa. Cancer Immunol Immunother. 2004 Jul;53(7):617-24. doi: 10.1007/s00262-003-0498-0. Epub 2004 Feb 7. Cancer Immunol Immunother. 2004. PMID: 15175906 Free PMC article.
Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, Tatsumi N, Sakaguchi N, Fujioka T, Masuda T, Yasukawa M, Udaka K, Kawase I, Oji Y, Sugiyama H. Fujiki F, et al. Among authors: elisseeva oa. J Immunother. 2007 Apr;30(3):282-93. doi: 10.1097/01.cji.0000211337.91513.94. J Immunother. 2007. PMID: 17414319
Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia.
Kawakami M, Oka Y, Tsuboi A, Harada Y, Elisseeva OA, Furukawa Y, Tsukaguchi M, Shirakata T, Nishida S, Nakajima H, Morita S, Sakamoto J, Kawase I, Oji Y, Sugiyama H. Kawakami M, et al. Among authors: elisseeva oa. Int J Hematol. 2007 Jun;85(5):426-9. doi: 10.1532/IJH97.06194. Int J Hematol. 2007. PMID: 17562620
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma.
Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi YC, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y, Kawakami M, Nakajima H, Nishida S, Shirakata T, Oka Y, Shuin T, Sugiyama H. Iiyama T, et al. Among authors: elisseeva oa. Microbiol Immunol. 2007;51(5):519-30. doi: 10.1111/j.1348-0421.2007.tb03940.x. Microbiol Immunol. 2007. PMID: 17579261 Free article. Clinical Trial.
Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
Tsuboi A, Oka Y, Nakajima H, Fukuda Y, Elisseeva OA, Yoshihara S, Hosen N, Ogata A, Kito K, Fujiki F, Nishida S, Shirakata T, Ohno S, Yasukawa M, Oji Y, Kawakami M, Morita S, Sakamoto J, Udaka K, Kawase I, Sugiyama H. Tsuboi A, et al. Among authors: elisseeva oa. Int J Hematol. 2007 Dec;86(5):414-7. doi: 10.1007/BF02983998. Int J Hematol. 2007. PMID: 18192109
25 results